Evidence map›Paper›PMID 42546369›Full record

ArticleDrug and alcohol dependence2026

Reproductive health considerations for HIV prevention integrated care models for women who inject drugs: Qualitative perspective of participants and providers in HIV Prevention Trials Network 094.

Maggie Albano, Rose A Schmidt, Kiyomi Tsuyuki, Steve Shoptaw, Nabila El-Bassel, Laramie R Smith, Jordan E Lake, Jayla Harris-Wisecarver, Philip Andrew, Cecile Denis and 4 more

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Maggie AlbanoHIV Prevention Trials Network, Family Health International 360, Durham, NC, United States.
Rose A SchmidtDepartment of Internal Medicine, School of Medicine, New Haven, CT, United States.
Kiyomi TsuyukiDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, United States.
Steve ShoptawDepartment of Family Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Nabila El-BasselSchool of Social Work, Columbia University, New York, NY, United States.
Laramie R SmithDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, United States.
Jordan E LakeDivision of Infectious Diseases, McGovern Medical School, UTHealth, Houston, TX, United States.
Jayla Harris-WisecarverHIV Prevention Trials Network, Family Health International 360, Durham, NC, United States.
Philip AndrewHIV Prevention Trials Network, Family Health International 360, Durham, NC, United States.
Cecile DenisPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Hannah YellinMilken Institute School of Public Health, George Washington University, Washington, DC, United States.
Sydney BornsteinMilken Institute School of Public Health, George Washington University, Washington, DC, United States.
Rashaunna ReddSchool of Social Work, Columbia University, New York, NY, United States.
Stephanie A Meyers-PanteleDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, CA, United States. Electronic address: s3meyers@health.ucsd.edu.

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
MassHEAL - Reducing overdose deaths by 40% (2019-2023)UM1DA049412 · NIDA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2019 to 2023
$82.9M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
LOTUS: An mHealth Intervention to Improve HIV Prevention Service Engagement and Intersectional Stigma among Racially Diverse Women Who Use DrugsK01DA055983 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Stephanie Alice Meyers-Pantele · 2022 to 2026
$941k
SALUD: Syndemic Alcohol Use Disorders, Violence, and HIV/STI in Young Latino MenK01AA025009 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TSUYUKI, KIYOMI · 2017 to 2021
$939k
Reducing HIV-related Intersectional Stigma and Risk among People who Inject Drugs in a High Risk International SettingR34DA059327 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, LARAMIE RAE · 2023 to 2025
$710k
CHAMPION - Combining HIV And Stimulant Prevention and Treatment Interventions Optimized for HIV-Negative MSMR21DA060856 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SANTOS, GLENN-MILO, TSUYUKI, KIYOMI · 2024 to 2025
$355k
NIAAA NIH HHS K01 AA025009NIAID NIH HHS P30 AI036214NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIDA NIH HHS K01 DA055983NIDA NIH HHS R21 DA060856NIDA NIH HHS R34 DA059327NIDA NIH HHS UM1 DA049412NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

backgroundCisgender women who inject drugs (WWID) face gendered health inequities and unique barriers to accessing healthcare services. We explored WWID's sexual and reproductive health (SRH) needs to inform the development of integrated care for this population.

methodsThe HPTN 094 (INTEGRA) study tested the efficacy of delivering mobile integrated services for people who inject drugs. Semi-structured interviews were conducted with 116 INTEGRA participants and staff to identify barriers and facilitators for medication for opioid use disorder (MOUD) and HIV prevention and treatment. We conducted a thematic analysis of qualitative data from 38 interviews (n = 23 participants; n = 15 staff; n = 31 cisgender women; n = 3 cisgender men; n = 3 nonbinary) containing narratives around WWID's SRH. Findings were contextualized within the Sexual and Reproductive Justice Framework (SRJF) to understand WWID's SRH experiences and to inform equitable integrated care.

resultsWe identified three themes related to SRJF. First, aligned with the justice-based perspective (i.e., the socio-structural factors impacting SRH), participants detailed the "real-life" implications of being a WWID, including the disproportionate reproduction, parenting, and household management responsibilities (i.e., "responsibility of care") that impede SRH service utilization. Second, participants highlighted how systemic barriers (i.e., limited access to specialized providers and pervasive stigma) undermine care. Third, aligned with the rights-based perspective (i.e., promoting reproductive freedom), participants underscored the importance of centering WWID's voices to inform equitable SRH services. DISCUSSION: Findings highlight the disproportionate responsibility of care WWID face, how this responsibility and stigma negatively impact SRH access, and the need for mobile, integrated care options that address the needs of WWID.

Indexed as

Delivery of Health Care, IntegratedHIV InfectionsReproductive HealthSubstance Abuse, IntravenousAdultFemaleHealth Services AccessibilityHumansMaleMiddle AgedQualitative ResearchHIV preventionInjection drug useIntegrated care modelsOpioid agonist treatmentPeople who use drugsSexual and reproductive healthWomen

Identifiers

PMID42546369
PMCPMC13649230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.